Ethylene oxide sterilization effectively kills microorganizms yet leaves invisible toxic residues that cause severe adverse events - hemolysis, neurotoxicity, and sensitization reactions make residual monitoring mandatory for patient safety. Ethylene oxide and ethylene chlorohydrin residual testing per ISO 10993-7 represents mandatory safety validation for all EtO-sterilized medical devices, with validated GC-FID headspace methodology achieving detection limits well below allowable limits established by ISO 10993-17. The validated methodology ensures accurate patient exposure assessment through simulated-use extraction protocols, with three sequential extractions generating dissipation curves modeling residue depletion during clinical use representing realistic patient exposure. Critical for validating aeration parameters ensuring adequate residue removal before product release, supporting batch release decisions demonstrating compliance with safety limits, and demonstrating regulatory compliance with exposure limits particularly stringent for pediatric and long-term implantable devices. The analysis enables optimization of sterilization cycles balancing microbial efficacy requiring adequate EtO exposure against minimized residue formation from reduced chemical contact and lower temperatures. For implantable devices particularly those contacting blood or neural tissue, EtO residues cause hemolysis and neurotoxicity at elevated levels, making rigorous testing essential for patient safety. The ethylene chlorohydrin measurement proves critical as this reaction product between EtO and chlorine forms during sterilization or aeration, exhibiting greater toxicity than EtO itself requiring separate quantification and limits. Manufacturing validation establishes aeration times achieving consistent residue reduction, while routine testing verifies process control maintaining residues within specifications across production lots and sterilization cycles.